HIGHLIGHTS
- who: Anna E. Harris et al. from the University of Molise, Italy have published the research: Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer, in the Journal: (JOURNAL)
- what: Therapeutic strategies targeting the AR function remain the cornerstone for treating men with advanced PCa.
- future: It found that olaparib improved rPFS and objective response rate in comparison to treatment with enzalutamide or abiraterone although concluded that further studies are required to better define the genetic mutations that will sensitize a cancer to olaparib . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.